CEConcepts Enduring: Addressing Unmet Needs in Advanced Endometrial Cancer: The Latest Advances for the Oncology Nurse

• Identify the predictive biomarkers that allow for tailored treatment options for patients with endometrial cancer, exploring the role of the oncology nurse in molecular testing.
• Appraise recent clinical evidence on the safety and efficacy of immune checkpoint inhibitor monotherapy and combinatorial regimens for the treatment of advanced or recurrent endometrial cancer.
• Analyze the unique toxicities of immune checkpoint inhibitors for endometrial cancer and important considerations for both monitoring and managing adverse events.
• Use a case-based approach to recognize and address socioeconomic and racial disparities affecting health outcomes in endometrial cancer patients and how the oncology nurse can provide patient-centric care that is both efficacious and equitable.

Supported through an independent educational grant from GlaxoSmithKline+Eisai+Merck.

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planner/Faculty:
Sirithepphavanh S. Oliver, NP–has disclosed that she is on the Speakers Bureau for GlaxoSmithKline.
Peer Reviewer:
Julie George, NP–has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff:
Tina L. Trieu, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.